Authors


Eric Edwards, MD, PhD

Latest:

Meeting the Need

The tide of deaths due to unintentional prescription opioid toxicity must be stemmed.


Patricia Hines, BA

Latest:

Impact of Drug Therapy Duration in Patients With Hepatitis C

Adherence to drug therapy in hepatitis C increased total costs in year 1 relative to nonadherent patients, then decreased total costs in year 2.



Shimona Yosselson Superstine, PharmD, MPH

Latest:

Large-Scale, Community-Based Trial of a Personalized Drug-Related Problem Rectification System

A controlled trial of a system for rectifying and preventing drug-related problems was conducted to evaluate improvement in the efficiency of resource utilization.



Joseph A. Woelfel, RPh, PhD

Latest:

Medicare Part D Optimization: Potential Out-of-Pocket Savings Through Plan Reexamination

Medicare Part D plans can change their cost-sharing structure and formularies every year. As such, beneficiaries should annually reevaluate plan offerings to minimize their out-of-pocket costs.


Nat Cooperman, Gene Yuan, Bobby Kaura, Bob Geissler, ThermaProx Inc.

Latest:

Can Thermal Mass Change the Cold Supply Chain?

Due to constantly changing business models, various product configurations and distribution channels, there is no established standard to ensure that a product administered to a patient is not compromised. 



Bhavesh Shah, RPh, BCOP

Latest:

Future Directions for the Treatment of CLL

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.


Jenny Powers, HCPLive

Latest:

Riluzole Shows No Efficacy as a Neuroprotective Agent in Patients with Early-Stage Relapsing Remitting Multiple Sclerosis

Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).


Jennifer Sutherland, PharmD

Latest:

Oxandrolone for Management of Hypercatabolism in Severe Burns

A case involving a 69-year-old man who is admitted to the burn center for management following a 31% full thickness burn and begins to lose significant lean body mass.


Adam Hochron

Latest:

Basaglar Receives Tentative FDA Approval for Diabetes Treatment

A new drug was recently given tentative approval by the FDA to help patients with both type 1 and type 2 diabetes.


Jennifer Barrow, PharmD

Latest:

Chronic Obstructive Pulmonary Disease

How should you treat this patient?


Teresa Chu, PharmD, BCPS

Latest:

Discussing Medication Adherence with a Hospitalized Patient

Medication adherence is defined as the act of patients taking their medications as prescribed by their health care provider.


Carolyn Colwell

Latest:

Clues Found to Long-Term HIV Suppression

South African child with HIV reaches 8-plus year survival after only 40 weeks of antiretroviral therapy in infancy.



Pallavi Rane, PhD

Latest:

Variation in the Coverage of Disease-Modifying Multiple Sclerosis Drugs Among US Payers

An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.


CEO, National Pharmaceutical Council

Latest:

Evidence: Vital but Seldom Used Consistently by Payers

Peer-reviewed research conducted by the National Pharmaceutical Council (NPC) and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on what’s behind discrepancies in coverage decisions from one insurer to the next.


Lauren Santye, Assistant Editor

Latest:

What Advice Would You Give to Patients?

Cancer patient Beth Wallace provides advice to patients with leiomyosarcoma, as well as to women with cancer in general.


Emily Bilas, PharmD

Latest:

Good Intentions: Writing the Letter of Intent

So, the initial meet and greet at Mid-Year went well. You have selected the 'perfect' program. Now, it is time to declare that intention in writing.



David M. Cook, MD

Latest:

Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives

Current treatment guidelines utilized by healthcare provider organizations and managed care organization insurance coverage policies for growth hormone therapy are reviewed.



Angelica Welch

Latest:

Oncology Biosimilars Bring Hope to Patients with Cancer

Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.



Silas Inman

Latest:

Bispecifics, CAR T Cells Among Most Exciting Recent Advances in Hematologic Malignancies

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.



Abby Christopher

Latest:

ROUNDTABLE DISCUSSION: "THE FUTURE OF PHARMACY"

Ms. Christopher is a freelance writer based in Portland, Ore.


Dr. Christina Tarantola, PharmD, CHC, CHt

Latest:

Utilizing the Stages of Change to Motivate Patients

How can you engage patients to adapt healthy behaviors and be adherent? Motivational Interviewing may be the missing piece.


Stephanie LaPointe, PharmD, CSPO, FMPA

Latest:

Precision Medicine and the Pharmacist’s Role as a Trusted Counselor in Specialty Pharmacy

The placement of clinical pharmacists at the nexus of functional pharmacogenomics and in specialty pharmacy care makes good sense.